Gilboa Mayan, Regev-Yochay Gili, Meltzer Eyal, Cohen Ido, Peretz Yovel, Zilberman-Daniels Tal, Segev Amitai, Amit Sharon, Yahav Dafna, Barda Noam
Faculty of Medical and Health Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.
The Sheba Pandemic Preparedness Research Institute, Sheba Medical Center, Ramat-Gan, Israel.
JAMA Netw Open. 2025 Aug 1;8(8):e2525252. doi: 10.1001/jamanetworkopen.2025.25252.
Clostridioides difficile is a leading cause of health care-associated infections. Understanding the association among C difficile carriage, antibiotic use, and infection hazard is essential for infection prevention.
To evaluate the hazard of C difficile infection (CDI) among asymptomatic carriers vs noncarriers of C difficile and whether it is associated with antibiotic exposure.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study conducted between June 18, 2017, and June 21, 2023, analyzed hospitalizations from Sheba Medical Center in Ramat Gan, Israel, which routinely screens for C difficile in high-risk patients admitted to internal medicine. Adult patients (aged >18 years) without active CDI at admission were included.
Antibiotic exposure during hospitalization, including specific classes.
The primary outcome was the development of CDI, as confirmed by laboratory testing for C difficile. Antibiotic exposure was assessed as a time-varying variable.
The study included 33 756 hospitalizations among 23 001 patients (median [IQR] age, 78 [68-87] years; 52.8% men). C difficile infection occurred in 67 of 1624 hospitalizations (4.1%) with positive screening results and in 47 of 32 132 hospitalizations (0.1%) with negative screening results. A positive C difficile screening result at admission was associated with a high hazard of infection (hazard ratio [HR], 27.5; 95% CI, 18.7-40.3). Antibiotic exposure was associated with an increased hazard for CDI (HR, 1.98; 95% CI, 1.24-3.16). Piperacillin and tazobactam showed the most pronounced hazard for CDI (HR, 2.18; 95% CI, 1.41-3.36). Among asymptomatic carriers, antibiotic exposure was not significantly associated with a further increase in CDI hazard (HR, 1.07; 95% CI, 0.73-1.58).
In this cohort study, carriers of C difficile had a substantially higher baseline hazard for hospital-onset CDI. Antibiotic exposure was associated with an increased hazard among noncarriers but was not significantly associated with additional hazard among carriers. These findings suggest that while antibiotic stewardship may reduce CDI risk in noncarriers, additional strategies may be needed for carriers given their elevated baseline risk.
艰难梭菌是医疗保健相关感染的主要原因。了解艰难梭菌携带、抗生素使用和感染风险之间的关联对于预防感染至关重要。
评估艰难梭菌无症状携带者与非携带者中艰难梭菌感染(CDI)的风险,以及其是否与抗生素暴露相关。
设计、设置和参与者:这项回顾性队列研究于2017年6月18日至2023年6月21日进行,分析了以色列拉马特甘舍巴医疗中心的住院情况,该中心对内科高危患者常规筛查艰难梭菌。纳入入院时无活动性CDI的成年患者(年龄>18岁)。
住院期间的抗生素暴露,包括特定类别。
主要结局为经艰难梭菌实验室检测确诊的CDI发生情况。抗生素暴露作为一个随时间变化的变量进行评估。
该研究纳入了23001名患者的33756次住院(年龄中位数[四分位间距],78[68 - 87]岁;男性占52.8%)。1624次筛查结果为阳性的住院中有67次发生CDI(4.1%),32132次筛查结果为阴性的住院中有47次发生CDI(0.1%)。入院时艰难梭菌筛查结果为阳性与感染高风险相关(风险比[HR],27.5;95%置信区间,18.7 - 40.3)。抗生素暴露与CDI风险增加相关(HR,1.98;95%置信区间,1.24 - 3.16)。哌拉西林和他唑巴坦显示出对CDI最显著的风险(HR,2.18;95%置信区间,1.41 - 3.36)。在无症状携带者中,抗生素暴露与CDI风险进一步增加无显著关联(HR,1.07;95%置信区间,0.73 - 1.58)。
在这项队列研究中,艰难梭菌携带者发生医院获得性CDI的基线风险显著更高。抗生素暴露在非携带者中与风险增加相关,但在携带者中与额外风险无显著关联。这些发现表明,虽然抗生素管理可能降低非携带者的CDI风险,但鉴于携带者基线风险较高,可能需要额外的策略。